With the above considerations, cost containment measures, and increasing patient access, the anti-CD38 monoclonal antibody daratumumab will continue to be incorporated into the region’s standard treatment regimens for plasma cell dyscrasias. The gene discussed is CD38; the disease is plasma cell neoplasm.